Subtopic Deep Dive
HER2 EGFR Signaling Pathways
Research Guide
What is HER2 EGFR Signaling Pathways?
HER2 EGFR signaling pathways encompass the dimerization, heterodimerization, and downstream activation cascades of ErbB family receptor tyrosine kinases that drive oncogenesis in cancers such as breast, lung, and colorectal.
These pathways involve EGFR (ErbB1) and HER2 (ErbB2) forming heterodimers that activate PI3K/AKT and MAPK signaling (Olayioye, 2000; 2419 citations). Key studies link wild-type KRAS to EGFR inhibitor efficacy in colorectal cancer (Amado et al., 2008; 3139 citations) and EGFR gene copy number to gefitinib response in NSCLC (Cappuzzo et al., 2005; 1566 citations). Over 10 high-citation papers detail pathway dynamics and therapeutic targeting.
Why It Matters
HER2 EGFR signaling pathways guide precision therapies like trastuzumab for HER2-positive breast cancer, improving disease-free survival (Slamon et al., 2011; 2733 citations), and panitumumab for KRAS wild-type colorectal cancer (Amado et al., 2008; 3139 citations). Pathway insights enable EGFR inhibitor selection in NSCLC based on FISH-detected gene amplification (Cappuzzo et al., 2005; 1566 citations) and glioblastoma response via EGFRvIII/PTEN coexpression (Mellinghoff et al., 2005; 1442 citations). Modeling crosstalk supports antibody-drug conjugate design (Fu et al., 2022; 1335 citations).
Key Research Challenges
Heterodimerization Complexity
EGFR-HER2 heterodimers activate diverse downstream signals, complicating inhibitor design (Olayioye, 2000; 2419 citations). Pathway crosstalk resists single-agent therapies (Sigismund et al., 2017; 1396 citations).
Downstream Resistance Markers
KRAS mutations block EGFR inhibitors in colorectal cancer (Amado et al., 2008; 3139 citations). PTEN loss predicts glioblastoma resistance to EGFR kinase inhibitors (Mellinghoff et al., 2005; 1442 citations).
Cell Line Heterogeneity Modeling
Breast cancer cell lines vary in HER2/EGFR expression, affecting pathway studies (Holliday and Speirs, 2011; 1500 citations). Accurate subtyping is needed for reliable signaling models.
Essential Papers
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Rafael G. Amado, Michael Wolf, Marc Peeters et al. · 2008 · Journal of Clinical Oncology · 3.1K citations
Purpose Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating m...
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis J. Slamon, W. Eiermann, Nicholas J. Robert et al. · 2011 · New England Journal of Medicine · 2.7K citations
The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracyc...
NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
Monilola A. Olayioye · 2000 · The EMBO Journal · 2.4K citations
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian et al. · 2020 · Breast Cancer Research · 2.4K citations
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi et al. · 2005 · JNCI Journal of the National Cancer Institute · 1.6K citations
High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC.
Choosing the right cell line for breast cancer research
Deborah L. Holliday, Valerie Speirs · 2011 · Breast Cancer Research · 1.5K citations
Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy base...
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
Ingo K. Mellinghoff, Maria Y. Wang, Igor Vivanco et al. · 2005 · New England Journal of Medicine · 1.4K citations
Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors.
Reading Guide
Foundational Papers
Start with Olayioye (2000; 2419 citations) for ErbB heterodimerization basics; Amado et al. (2008; 3139 citations) for downstream KRAS; Slamon et al. (2011; 2733 citations) for HER2 therapy evidence.
Recent Advances
Sigismund et al. (2017; 1396 citations) on EGFR functions; Fu et al. (2022; 1335 citations) on conjugates; Yin et al. (2020; 2369 citations) for subtyping.
Core Methods
FISH for EGFR amplification (Cappuzzo et al., 2005); gene expression profiling in cell lines (Holliday and Speirs, 2011); PTEN/EGFRvIII coexpression assays (Mellinghoff et al., 2005).
How PapersFlow Helps You Research HER2 EGFR Signaling Pathways
Discover & Search
Research Agent uses searchPapers and citationGraph to map HER2-EGFR heterodimerization from Olayioye (2000; 2419 citations), then findSimilarPapers reveals downstream KRAS links (Amado et al., 2008). exaSearch uncovers recent crosstalk in glioblastoma (Mellinghoff et al., 2005).
Analyze & Verify
Analysis Agent applies readPaperContent to extract signaling cascades from Sigismund et al. (2017), verifies KRAS wild-type claims with CoVe against Amado et al. (2008), and runs PythonAnalysis for pathway network statistics using NetworkX on expression data. GRADE grading scores evidence strength for inhibitor synergies.
Synthesize & Write
Synthesis Agent detects gaps in EGFR-HER2 resistance modeling, flags contradictions between NSCLC (Cappuzzo et al., 2005) and breast cancer studies. Writing Agent uses latexEditText, latexSyncCitations for pathway diagrams, and latexCompile to generate manuscripts with exportMermaid for dimerization graphs.
Use Cases
"Analyze signaling data from HER2-positive cell lines for MAPK activation rates"
Research Agent → searchPapers (Holliday 2011) → Analysis Agent → runPythonAnalysis (pandas/matplotlib on extracted expression data) → statistical plots of pathway activation.
"Draft LaTeX review on EGFR-HER2 heterodimers with citations"
Synthesis Agent → gap detection (Olayioye 2000) → Writing Agent → latexEditText + latexSyncCitations (Amado 2008, Slamon 2011) → latexCompile → formatted PDF review.
"Find code for modeling EGFR inhibitor synergies"
Research Agent → paperExtractUrls (Herbst 2004) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Python scripts for pathway simulations.
Automated Workflows
Deep Research workflow scans 50+ ErbB papers via citationGraph from Olayioye (2000), producing structured reports on dimerization cascades. DeepScan applies 7-step CoVe to verify KRAS-EGFR links (Amado et al., 2008) with GRADE checkpoints. Theorizer generates hypotheses on HER2 crosstalk synergies from Sigismund et al. (2017).
Frequently Asked Questions
What defines HER2 EGFR signaling pathways?
HER2 EGFR pathways involve ErbB receptor dimerization activating MAPK/PI3K cascades in cancer (Olayioye, 2000; 2419 citations).
What are key methods for studying these pathways?
FISH detects EGFR copy number for inhibitor response (Cappuzzo et al., 2005; 1566 citations); cell line profiling models heterogeneity (Holliday and Speirs, 2011; 1500 citations).
What are foundational papers?
Olayioye (2000; 2419 citations) reviews heterodimerization; Amado et al. (2008; 3139 citations) links KRAS to EGFR therapy; Slamon et al. (2011; 2733 citations) validates trastuzumab.
What open problems exist?
Resistance via PTEN loss (Mellinghoff et al., 2005; 1442 citations) and crosstalk need better models; triple-negative subtypes lack clear targeting (Yin et al., 2020; 2369 citations).
Research HER2/EGFR in Cancer Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HER2 EGFR Signaling Pathways with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the HER2/EGFR in Cancer Research Research Guide